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Abstract  
Series of indoline derivatives were synthesized using N-(4-aminophenyl) indoline-1-carbothiamide as a precursor. The 
structures of synthesized compounds were confirmed by   FT-IR, 
1
H-NMR, 
13
C-NMR and LC-MS. The in vitro anti-
inflammatory activity of synthesized indoline derivatives were examined by standard anti-denaturation assay. The 
compounds 4a (IC50 = 62.2 µg/ml) and 4b (IC50 = 60.7 µg/ml) showed potent inhibition on protein denaturation. The 
compounds 5a (IC50 = 97.8 µg/ml) exhibits moderate inhibition on protein denaturation.   
Keywords: indoline, anti-inflammatory , anti-denaturation, 
1
H-NMR . 
1. Introduction 
Heterocyclic compounds containing five or six membered ring are essential for their various biological activities [1]. 
Indoline the potent basic pharmacodynamic nucleus, has been reported to possess a wide variety of biological properties 
such as antimicrobial [2-5], anticancer [6-10], anti-diabetic [11], anti-inflammatory [12-13], antitubulin[14], anti-
hyperlipidemic [15], anti-atherosclerotic [15], anticoagulant [16], tyrosinekinase inhibitor [17], antiperoxidative [18], 
antioxidant [19], anti-hepatocellularcarcinoma [20], Antimitoic [21]
 
and Antagonists[22-23].  
In addition, the indoline nucleus is incorporated in various natural products such as alkaloids [24]. Encouraged by the 
above observations and considering the interesting pharmacological profile of indoline, we synthesized N-(4-
aminophenyl)indoline-1-carbothioamide scaffold based compounds as anti-inflammatory agents. The biological activity 
and structure–activity relationship (SARs) of the newly synthesized indoline derivatives discussed.  
2. EXPERIMENTAL  
2.1. Chemistry  
The synthetic starting materials such as reagents and solvents were used in analytical grade or the highest quality 
commercially available and were purchased from Sigma-Aldrich Chemical Co., Merck Chemical Co. Melting points were 
recorded by labtronics digital melting points apparatus. The 
1
H-NMR and 
13
C-NMR spectra were recorded in DMSO-d6 
solvent on Bruker 300 MHz spectrophotometer using tetramethylsilane as an internal reference. The apparent resonance 
multiplicity is described as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), td (triplet of doublet), q (quartet) and m 
(multiplet). Infrared measurements were recorded in the range 400-4000 cm
-1
 by Perkin Elmer. Mass spectra were 
recorded on a Thermo LCQ Deca XP MAX at 70eV. Thin layer chromatography (TLC) analysis was carried out on 5 x 20 
cm plate coated with silica gel GF254. 
2.1.1. Synthesis of   N-(4-nitrophenyl) indoline-1-carbothioamide (1) 
To a solution of indoline (10 g, 0.0835 mol) in 200 mL of THF, 4-nitrophenyl isothiocyanate (16.53 g, 0.0918 mol) was 
added at 0
o
C. The resulting reaction mass was allowed to RT and stirred for 4 hr. The reaction mass was concentrated 
under reduced pressure to give the compound 1 as a yellow solid; Yield 80%; m.p 173-174 
O
C; IR (KBr) νmax in cm
-1
 : 
3434, 3300 (NH stretch), 3074 (CH stretch, aromatic), 2919, 2850 (CH stretch, aliphatic), 1532, 1319, (NO2 stretch), 1477 
(CH2 bend), 1270 (C=S), 909 (C-N stretch) ; 
1
H-NMR (DMSO-d6) δ ppm: 3.13 (t, 2H, J = 8.1 Hz), 4.32 (t, 2H, J = 8.2 Hz), 
7.05 (td, 1H,  J = 0.9, 7.9 Hz), 7.18 (td, 1H, J = 1.2, 8.1 Hz), 7.33 (d, 1H, J = 7.9 Hz), 7.71 (d, 2H,  J = 9.9 Hz), 7.80 (d, 1H, 
J = 8.0 Hz), 8.19 (d, 2H, J = 9.9 Hz), 10.39 (s,1H ); 
13
C-NMR (DMSO-d6) δ ppm: 26.6, 54.2, 116.0, 121.9, 123.9, 124.1, 
125.6, 126.8, 134.3, 142.1, 142.2, 146.8, 177.5; LC-MS calculated for (C15H13N3O2S) m/z [M + H]
+
 299.07, found m/z  
300.0665. 
2.1.2. Synthesis of N-(4-aminophenyl) indoline-1-carbothioamide (2) 
To a solution of compound 1 (10 g, 0.0338 mol) in 100 mL 12N HCl, SnCl2 (63.88 g, 0.338 mol) was added at RT. The 
resulting reaction mass was stirred for 3 hr. The completion of the reaction was monitored by TLC. The reaction mass was 
diluted with 350 mL of cold water. The resulting reaction mass was basified to pH 8 with 40% NaOH. The aqueous layer 
was extracted with ethyl acetate (3 x 150 mL) and water (2 x 30 mL), brine (1 x 300 mL) and dried over anhydrous 
Na2SO4. The organic layer was concentrated under reduced pressure to afford compound 2. Brown solid; Yield 72% ; mp 
209-210 
o
C; IR (KBr) νmax in cm
-1
 :
 
 3398 (NH stretch), 3055 (CH stretch, aromatic), 2969 (CH stretch, aliphatic), 1610 (NH 
bend), 1447 (CH2 bend), 1209 (C=S), 932 (C-N stretch) ; 
1
H-NMR (DMSO-d6) δ ppm: 3.08 (t, 2H, J = 8.1 Hz), 4.21 (t, 2H, 
J = 8.2 Hz), 5.05 (s, 2H), 6.52 (d, 2H, J = 8.7 Hz),  6.95 (t, 3H,  J = 7.2 Hz), 7.12 (t, 1H, J = 7.8 Hz), 7.24 (d,1H, J = 7.9 
Hz), 8.29 (d, 1H, J = 8.1 Hz), 9.41 (s, 1H) ;
 13
C-NMR (DMSO-d6) δ ppm: 26.7, 52.8, 113.3, 116.1, 122.5, 124.9, 126.1, 
126.8, 128.5, 133.3, 143.4, 146.3, 178.5; LC-MS calculated for (C15H15N3S) m/z [M + H]
+
 269.100, found m/z  270.0979.     
2.1.3. Synthesis of 1-(4-fluorophenyl)-3-(4-(indoline-1-carbothioamido)phenyl)thiourea (3a) 
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To a solution of compound 2 (0.4 g, 0.0015 mol) in 12 mL THF, 4-fluoro phenyl isothiocyanate (0.300 g, 0.0019 mol) was 
added at 0
o
C. The reaction mixture was allowed to RT and stirred for 2 hr. The progress of the reaction was monitored by 
TLC. The reaction mass was concentrated under reduced pressure and separated between ethyl acetate (1 x 50 mL) and 
2N HCl (1 x 25 mL). The resulting ethyl acetate layer was washed with brine (1 x 40 mL) and dried over anhydrous 
Na2SO4. The ethyl acetate layer was concentrated under reduced pressure to afford compound 3a. Pal yellow solid; Yield 
32%; mp 259-261 
o
C; IR (KBr) νmax in cm
-1 
: 3424 (NH stretch), 2926 (CH stretch, aromatic), 2581 (CH stretch, aliphatic), 
1590 (NH bend), 1449 (CH2 bend), 1291 (C-N stretch), 1211 (C=S), 761 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 3.10 (t, 
2H, J = 8.3 Hz), 4.26 (t, 2H, J = 8.1 Hz), 6.99   (t, 1H, J = 7.8 Hz),  7.13-7.15 (m, 3H), 7.29 (d, 1H, J = 8.3 Hz), 7.27-7.50 
(m, 6H), 8.09 (d, 1H, J = 8.4 Hz), 9.76 (s, 3H) ;
 13
C-NMR (DMSO-d6) δ ppm: 26.7, 53.3, 114.8, 115.1, 123.0, 123.6, 125.2, 
126.0, 126.4, 133.7, 135.7, 143.0, 157.8, 160.2,178.2, 179.9; LC-MS calculated for (C22H19FN4S2) m/z [M + H]
+  
422.1, 
found m/z  423.0681.
 
2.1.4. Synthesis of 1-(4-(indoline-1-carbothioamido) phenyl)-3-(3-methoxy phenyl)urea  (3b) 
To a solution of compound 2 (0.5 g, 0.0018 mol) in 15 mL THF, 3-methoxy phenyl isocynate (0.322 g, 0.0024 
mol) was added at 0
o
C. The reaction was carried out at RT and stirred for 1 hr. The completion of reaction was monitored 
by TLC. To the resulting residue, diethyl ether was added and the solid was filtered off. The resulting white solid was dried 
under vacuum to afford compound 3b. Yield 76% ; mp 246-248 
o
C ; IR (KBr) νmax in cm
-1 
: 3287 (NH stretch), 2950 (CH 
stretch, aromatic), 2838 (CH stretch, aliphatic),  1649 (C=O), 1558 (NH bend), 1491 (CH2 bend), 1291 (C-N amide), 1230 
(C=S), 1160 (C-O), 763 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 3.10 (t, 2H, J = 8.1 Hz), 3.70 (s, 3H), 4.27 (t, 2H, J = 8.1 
Hz), 6.52 (dd, 1H, J = 2.1, 8.1 Hz), 6.92-7.00 (m, 2H), 7.11-7.27 (m, 6H), 7.43 (d, 2H, J = 8.7 Hz), 8.23 (d, 1H, J = 8.2 Hz), 
9.41 (d, 2H, J = 9.1 Hz), 9.67 (s, 1H) ; 
13
C-NMR (DMSO-d6) δ ppm: 26.7, 53.1, 54.8, 103.5, 106.8, 110.1, 116.1, 117.6, 
122.8, 125.0, 125.8, 126.2, 129.4, 133.6, 136.9, 141.2, 141.2, 143.2, 152.7, 159.6, 178.4 ; LC-MS calculated for 
(C23H22N4O2S) m/z [M + H]
+
418.15, found m/z  419.1155.  
2.1.5. Synthesis of N-(4-(tosylamino) phenyl) indoline-1-carbothio amide (4a) 
To a solution of compound 2 (0.4 g, 0.00150 mol) in 10 mL THF, pyridine (0.474 mL, 0.006 mol) was added at 
0
o
C  followed by  4-toluene sulfonyl chloride (0.285 g, 0.00150 mol)  in 2 mL 1,2-dichloroethane was  added . The reaction 
mixture was allowed to RT and stirred for 3 hr. The progress of the reaction was monitored by TLC. The reaction mixture 
was concentrated under reduced pressure and separated between ethyl acetate (50 mL) and water (50 mL). The 
combined ethyl acetate layer was washed with 2N HCl (1 x 30 mL), 10 % NaHCO3 (2 x 25 mL), brine (2 x 50 mL) and 
dried over anhydrous Na2SO4. The ethyl acetate layer was concentrated under reduced pressure to afford compound 4a. 
White solid; Yield 48 % mp 220-222
 o
C; IR (KBr) νmax in cm
-1   
: 3423 (NH stretch), 3282, 3059 (CH stretch, aromatic), 2921 
(CH stretch, aliphatic), 1595 (NH bend), 1516 (CH2 bend),  1371, 1154 (S=O), 749 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 
2.34 (s, 3H), 3.08 (t, 2H, J = 8.4 Hz), 4.22 (t, 2H, J = 8.4 Hz), 6.95-7.09 (m, 3H), 7.11 (t, 1H, J = 7.8 Hz), 7.20-7.27 (m, 
3H), 7.35 (d, 2H, J = 8.1 Hz), 7.64 (d, 2H, J = 8.1 Hz), 8.9 (d, 1H, J = 8.1 Hz), 9.63 (s, 1H), 10.18 (s, 1H); 
13
C-NMR 
(DMSO-d6) δ ppm: 20.9, 26.6, 53.1, 116.0, 120.1, 123.0, 125.1, 125.66, 126.3, 126.6, 129.6, 133.6, 134.2, 136.2, 136.7, 
142.8, 143.1, 178.1; LC-MS calculated for (C22H21N3O2S2) m/z [M + H]
+ 
423.11, found m/z  424.0771. 
2.1.6. Synthesis of N-(4-{[(2,6-dichlorophenyl)sulfonyl ]amino}phenyl) indoline-1-carbothio 
amide (4b) 
Prepared as reported above for 4a, starting from compound 2 and 2,6-dichlorobenzene-1-sulfonyl chloride. This 
reaction was carried out at room temperature for 3  hr. Red solid; Yield 37 % ; mp 215-217
 o
C ; IR (KBr) νmax in cm
-1 
: 3432 
(NH stretch), 3360, 3099 (CH stretch, aromatic), 2922, 2850 (CH stretch, aliphatic), 1600 (NH bend), 1519 (CH2 bend), 
1387, 1165 (S=O), 747 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 3.09 (t, 2H, J = 8.1 Hz), 4.21 (t, 2H, J = 8.2 Hz), 7.04-7.07 
(m, 2H), 7.14 (d, 1H, J = 8.5 Hz), 7.23-7.26 (m, 3H), 7.52-7.71 (m, 3H), 8.10 (d, 1H, J = 8.4 Hz), 9.63 (s,1H), 10.78 (s,1H) ; 
13
C-NMR (DMSO-d6)  δ ppm: 27.1, 53.7, 116.5, 119.6, 123.5, 125.6, 126.3, 126.8, 127.6, 130.7, 132.4, 133.7, 134.2, 
134.92, 136.8, 143.4,178.7 ; LC-MS calculated for (C21H17Cl2N3O2S2) m/z [M + H]
+  
477.01, found m/z  477.9745 
2.1.7. Synthesis of 2-(1H-indol-3-yl)-N-(4-(indoline-1-carbothio amido) phenyl) acetamide                                                                     
(5a) 
To a solution of compound 2 (0.4 g, 0.00150 mol) in 12 mL , 3-indole acetic acid (0.316 g, 0.00181 mol), 
EDC.HCl (0.370 g, 0.00195 mol) and HOBt (0.202 g, 0.00150 mol) was added.  The mixture was cooled to 0
o
C and 
triethylamine (0.818 mL, 0.006 mol) was added. The resulting solution was allowed to RT and stirred for 8 hr. The reaction 
was monitored by TLC. The reaction mixture was concentrated under reduced pressure and resulting crude product was 
separated between ethyl acetate (50 mL) and water (50 mL). The combined ethyl acetate layer was washed with 2N HCl 
(1 x 30 mL), 10% NaHCO3 (2 x 20 mL), brine (2 x 50 mL) and dried over anhydrous Na2SO4.. The organic layer was 
concentrated under reduced pressure to afford compound 5a. Pal yellow solid; Yield 40%; mp 243-245
 O
C; IR (KBr) νmax in 
cm
-1 
: 3406 (NH stretch), 3310, 3184 (CH stretch, aromatic), 2904 (CH stretch, aliphatic), 1657 (C=O), 1527 (NH bend), 
1482 (CH2 bend), 1291 (C-N), 1254 (C=S), 788 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 3.09 (t, 2H, J = 8.1 Hz), 3.72 (s, 
2H), 4.24 (t, 2H, J = 8.1 Hz), 6.97 (td, 2H, J = 1.2, 6.9 Hz), 7.0-7.15 (m, 2H), 7.28  (m, 4H), 7.35 (d, 1H, J = 8.1 Hz), 7.54 -
7.62 (m,3H), 8.16 (d, 1H, J = 8.3 Hz), 9.67 (s, 1H), 10.12 (s, 1H), 10.92 (s, 1H) ; 
 13
C-NMR (DMSO-d6) δ ppm: 26.7, 33.7, 
53.1, 108.6, 111.35, 116.0, 118.3, 118.6, 118.9, 120.9, 122.9, 123.8, 125.1, 126.3, 127.2, 133.6, 135.0, 136.1, 136.2, 
143.1, 169.5, 178.4 ; LC-MS calculated for (C25H22N4OS) m/z [M + H]
+
426.15, found m/z  427.1205. 
2.1.8. Synthesis of 3-fluoro-N-(4-(indoline-1-carbothio amido)phenyl)benzamide (5b) 
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Prepared as reported above for 5a, starting from compound 2 and 3-fluorobenzoic acid. This reaction was carried 
out at RT for 7 hr. White solid; Yield 24 % ; mp 220-222
 o
C ;  IR (KBr) νmax in cm
-1 
: 3422 (NH), 3336, 3271 (CH stretch 
aromatic), 2930 (CH stretch aliphatic), 1657 (C=O), 1593 (NH bend), 1516 (CH2 bend), 1388 (C-F), 1317 (C-N), 746 (CH 
bend); 
1
H-NMR (DMSO-d6) δ ppm: 3.17 (t, 2H, J = 8.1 Hz), 4.27 (t, 2H, J = 8.4 Hz), 6.99 (t, 1H,  J = 7.2 Hz), 7.15 (t, 1H, J 
= 8.1 Hz), 7.32 (d, 1H, J = 7.2 Hz), 7.36 (d, 2H, J = 8.7 Hz), 7.47 (t, 1H, J = 7.8 Hz), 7.56-7.63 (m, 1H), 7.71 (d, 2H, J = 8.5 
Hz), 7.76-7.83 (m, 2H), 8.15 (d, 1H, J = 8.4 Hz), 9.75 (s, 1H), 10.33 (s,1H) ;
 13
C-NMR (DMSO-d6) δ ppm: 26.7, 53.2, 114.5, 
116.0, 118.3, 120.3, 123.8, 125.1, 126.3, 130.5, 130.6, 133.7, 135.5, 135.8, 137.2, 143.0, 160.7, 163.1, 163.9, 178.4 ; LC-
MS calculated for (C22H18FN3OS) m/z [M + H]
+
 391.12, found m/z  392.0887 
2.1.9. Synthesis of 2-(2-fluorophenyl)-N-(4-(indoline-1-carbothio amido) phenyl)acetamide (5c) 
Prepared as reported above for 5a, starting from compound 2 and 2-fluoro phenylacetic acid. This reaction was 
carried out at RT for 7 hr. Yellow solid; Yield 24 % ; mp 220-222
 o
C ; IR (KBr) νmax in cm
-1 
: 3328 (NH stretch), 3289, 3066 
(CH stretch, aromatic), 2632 (CH stretch, aliphatic), 1672 (C=O), 1600 (NH bend), 1510 (CH2 bend), 1388 (C-F), 1317 (C-
N), 744 (CH bend); 
1
H-NMR  (DMSO-d6) δ ppm: 3.10 (t, 2H, J = 8.4 Hz), 3.73 (s, 2H), 4.25 (t, 2H, J = 8.4 Hz), 6.97 (t, 1H, 
J = 6.6 Hz), 7.11-7.21 (m, 3H), 7.27 (d, 4H, J = 6.8 Hz), 7.31-7.42 (m, 1H), 7.54 (d, 2H, J = 8.6 Hz), 8.16 (d, 1H, J = 8.3 
Hz), 9.69 (s, 1H), 10.23 (s, 1H) ; 
13
C-NMR (DMSO-d6) δ ppm: 26.7, 36.2, 53.1, 115.1, 116.0, 118.9, 122.9, 123.0, 124.1, 
125.1, 126.3, 128.7, 128.7, 131.9, 133.6, 135.2, 143.0, 159.4, 161.8, 167.8, 178.4 ; LC-MS calculated for (C23H20FN3OS) 
m/z [M + H]
+ 
405.13, found m/z  406.0980. 
2.1.10. Synthesis of N-(4-(indoline-1-carbothio amido) phenyl)cyclopentanecarboxamide   
(5d)   
Prepared as reported above for 5a, starting from compound 2 and cyclopentane carboxylic acid. This reaction 
was carried out at RT for 8 hr. White solid; Yield 27 % ; mp 213-215
 o
C ; IR (KBr) νmax in cm
-1 
: 3298 (NH stretch), 3040 
(CH stretch, aromatic), 2928, 2860  (CH stretch, aliphatic), 1670 (C=O), 1602 (NH bend), 1518 (CH2 bend), 1317 (C-N), 
744 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 1.56-1.748 (m, 7H), 1.84 (d, 2H, J = 8.1 Hz), 3.10 (t, 2H, J = 8.1 Hz), 4.25 (t, 
2H, J = 8.4 Hz), 6.98 (t, 1H, J = 7.5 Hz), 7.13 (t, 1H, J = 7.5 Hz), 7.27 (d, 3H, J = 8.4 Hz), 7.55 (d, 2H, J = 8.7 Hz), 8.16 (d, 
1H, J = 8.1 Hz), 9.70 (s, 1H), 9.82 (s, 1H) ; 
13
C-NMR (DMSO-d6) δ ppm: 26.1, 27.2, 30.5, 45.7, 53.6, 116.5, 119.4, 123.43, 
125.6, 125.8, 126.8, 134.1, 135.4, 136.8, 143.6, 174.6, 178.9 ; LC-MS calculated for (C21H23N3OS) m/z [M + H]
+
 365, 
found m/z  366.1384. 
2.1.11. Synthesis of N-(4-(indoline-1-carbothio amido) phenyl)acetamide (5e) 
To a soluction of compound 2 (0.4 g, 0.00150 mol) in 10 mL of THF, triethylamine (0.757 mL, 0.0075 mol) was 
added at 0
o
C followed by acetyl chloride was added. The reaction mixture was allowed to RT and stirred for 1 hr. The 
reaction was monitored by TLC. The reaction mass was concentrated under reduced pressure and separated between 
ethyl acetate (50 mL) and water (50 mL). The combined ethyl acetate layer was washed with 2N HCl (1 x 25 mL), 10 % 
NaHCO3 (2 x 20 mL), brine (2 x 50 mL) and dried over anhydrous Na2SO4. The ethyl acetate layer was concentrated under 
reduced pressure to afford compound 5e, white solid; Yield 42 % mp 200-202
 O
C; IR (KBr) νmax in cm
-1 
: 3428 (NH stretch), 
3303, 3044 (CH stretch, aromatic), 2928 (CH stretch, aliphatic), 1661 (C=O), 1600 (NH bend), 1517 (CH2 bend), 1315 (C-
N), 743 (CH bend); 
1
H-NMR (DMSO-d6) δ ppm: 2.21 (s, 3H), 3.10 (t, 2H, J = 8.4 Hz), 4.25 (t, 2H, J = 8.4 Hz), 6.9 (t, 1H, J 
= 7.5 Hz), 7.14 (t, 1H, J = 7.5 Hz), 7.27 (d, 3H, J = 8.7 Hz), 7.52 (d, 2H, J = 8.7 Hz), 8.16 (d, 1H, J = 8.5 Hz), 9.67 (s, 1H), 
9.94 (s, 1H) ; 
13
C-NMR (DMSO-d6) δ ppm: 23.9, 26.5, 116.0, 118.8, 122.9, 125.4, 126.3, 133.6, 134.9, 136.1, 143.0, 
168.0, 178.4 ; LC-MS calculated for (C17H17N3OS) m/z [M + H]
+ 
 311.11, found m/z  312.0977. 
2.2. PHARMACOLOGY 
2.2.1. In vitro anti-inflammatory activity (Anti-denaturation assay) 
The experiment was carried out with small modification [25]. The standard drug and synthesized compounds 
were dissolved in minimum quantity of dimethyl Formamide (DMF) and diluted with phosphate buffer (0.2 M, PH 7.4). Final 
concentration of DMF in all solution was less than 2.5 %. Test solution (4 ml) containing different concentrations of drug 
was mixed with 1 ml of 1mM albumin solution in phosphate buffer and incubated at 37°C in incubator for 15 min. 
Denaturation was induced by keeping the reaction mixture at 70°C in water bath for 15 min. After cooling, the turbidity was 
measured at 660 nm. Percentage of inhibition of denaturation was calculated from control where no drug was added. The 
diclofenac sodium was used standard drug. The percentage inhibition of denaturation was calculated by using the 
following formula.   
% of Inhibition = (At - Ac) x 100 / At  
At = O.D. of test solution  
Ac = O.D. of control 
 3. RESULTS AND DISCUSSION  
 3.1 Chemistry   
The synthetic scheme for the preparation of intermediates and final compounds are shown in scheme (1-3). The 
intermediate-1 was prepared [26]
 
by using the reagent 4-nitrophenyl isothiocyanate. The FT-IR spectrum of intermediate-1 
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had characteristic NH absorption peaks at 3434 cm
-1
 and 3300 cm
-1
. The absorption peaks for C=S seen at 1270 cm
-1
. 
The NO2 stretching frequency observed at 1319 cm
-1 
and 1532 cm
-1
. In the 
1
H-NMR spectra of compound-I, the proton 
signal of thiourea NH was observed at δ 10.39 (1H, singlet). Characteristic peaks of thiocarbamide compound were 
observed at δ 10.39 ppm.  In 
13
C-NMR of intermediate-2, the characteristic peaks at thiocarbamide C=S resonate at 177.5 
ppm. The intermediate-2 was prepared [27]
 
by reduction of intermediate-1 by SnCl2. The FT-IR spectra of intermediate-2 
showed absorption band at 3398 cm
-1
 due to NH stretching vibration from resulting amine group formed. In the FT-IR 
spectrum of intermediate-2, the reduction of NO2 group was confirmed by disappearance of NO2 stretching vibration at     
1319 cm
-1 
and 1532 cm
-1
. In the 
1
H-NMR spectra of intermediate-2, the characteristic amine proton peak seen as broad 
singlet at δ 5.05 ppm. The resulting compound was also confirmed by TLC, which was exhibited ninhydrin activity. The 
intermediate-2 was taken a common scaffold for synthesis of proposed indoline derivatives. The synthetic path way for 
intermediate-2 is outlined below. 
Scheme-1 
 
Scheme.1. Reagents and conditions: (i). 4-nitrophenyl isothiocyanate, THF, 0
 o
C ;                             (ii) SnCl2, 
12N HCl, RT , 0
 o
C. 
The sulfonamide derivates 4a and 4b were prepared [28]
 
by reaction between corresponding sulfonyl chloride and key 
intermediate-2. The reacton was carried out in dichloroethane with pyridine base at 90
 o
C. The FT-IR spectrum resulted in 
sulfonamide derivatives exhibited absorption wave length at 1154 cm
-1
 and 1387 cm
-1
. Which is the characteristic peak of 
(S=O) group. The 
1
H-NMR spectra of synthesized sulfonamide derivatives showed new singlet peak at δ 9.63 ppm. 
The desired title compounds 3a and 3b were obtained in resonable yield [29] by treating key intermediate-2 with 
corresponding isocyanate and isothiocyanate respectively. In the FT-IR spectrum of 3a characteristic C=S seen at 1211 
cm
-1 
while in 3b characteristic C=O 1649 cm
-1
. In the 
1
H-NMR of 3a, NH proton of thiourea group resonated at δ 9.78 ppm. 
In the case of 3b, NH proton of new urea group resonated at δ 9.67 ppm. According to 
13
C-NMR of 3a and 3b, the 
compounds has displayed characteristic thiourea carbonyl carbon C=S at δ 179.9 ppm and urea carbonyl carbon C=O at δ 
159.6 ppm. The synthetic scheme for preparation of sulfonaminde, urea and thiourea derivatives are shown in Scheme-2.       
 
Scheme-2 Reagents and conditions (i). Pyridine,  Dichloroethane, 90
 o
C. (ii). THF, 0
o
C. 
From the above key intermediate-2, the carboxamide derivatives (5a-d) were prepared[30]
 
 by using reagent 1-
Ethyl -3-(3-dimethylaminopropyl) carbodiimide (EDCI). The corresponding acid chloride was used for preparing [31] the 
amide derivatives 5e. The FT-IR spectrum of all the carboxamide derivatives has strong C=O absorption, which showed 
wave length between 1657-1672 cm
-1
. The 
1
H-NMR spectra of all carboxamide derivatives exhibited broad singals at δ 
9.7-10.1ppm is assigned to NH. In addition, 
13
C-NMR spectra of all carboxamide derivatives displayed signals at δ 163.9-
174.6 ppm. All the FT-IR, 
1
H-NMR and mass spectral  data of compounds (5a-e)  were in accordance with the proposed 
molecular structures. The purity of synthesized compounds was monitored by TLC. The synthetic scheme for the 
preparation of all carboxamide derivatives are depicated in    Scheme-3. 
1 
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Scheme-3. Reagents and conditions (i). TEA, MDC, 0
o
C., (ii). EDCI, HOBt, TEA, THF, 0
o
C;  
3.2 Anti-inflammatory activity 
The anti-inflammatory activities of all the above indoline derivatives were examined by standard anti-denaturation 
assay. The inhibition efficiency of all synthesized indoline derivatives were tested at a concentration ranging from 50 µg/ml 
to 250 µg/ml. The percentage of inhibition and IC50 values of all indoline derivatives are listed in Table 1. The anti-
denaturation activity study related that the indoline derivatives 4a (IC50 = 62.2 µg/ml) and 4b (IC50 = 60.7 µg/ml) showed 
excellent inhibition activity that is comparable with standard drug diclofenac sodium (IC50 = 54.2 µg/ml). Furthermore, in 
the carboxamide derivatives particularly compound 5a (IC50 = 97.8 µg/ml) showed moderate anti-denaturation activity. The 
derivatives 3a (IC50 = 115.4 µg/ml) and 3b (IC50 = 109.1 µg/ml) were found to be significant anti-denaturation activity. The 
compounds 5c, 5d and 5e did not show noticeable activity. 
Table 1. Anti-inflammatory activity of indoline derivatives (anti-denaturation assay) 
 
 
compound 
 
 
 
% inhibition 
 
IC50 
(µg/ml)  
50 µg/ml 
 
 
100 µg/ml 
 
150 µg/ml 
 
200 µg/ml 
 
250 µg/ml 
3a 33.3 52.7 58.6 65.3 70.4 115.4 
3b 35.4 53.1 60.1 64.9 69.7 109.1 
4a 45.3 60.1 68.3 80.7        86.9 62.2 
4b 44.5 61.1 69.3 81.2 86.3 60.7 
5a 39.2 51.6 61.3 70.6 81.8 97.8 
5b 17.3 27.5 45.3 59.4 64.7 180.1 
5c 30.4 43.7 55.2 60.3 67.8 142.5 
5d 19.2 30.4 45.6 58.4 64.3 177.4 
5e 19.8 27.4 40.3 51.1 60.7 198.8 
Diclofenac 
sodium 
47.3 61.8 70.6 81.5 90.4 54.2 
 
The in vitro anti-inflammatory study revelated that the synthesized final compound, containg sulfonamide group showed 
very good inhibition on protein denaturation. Furthermore, carboxamide based final compound bearing indole acetic acid 
group showed significant activity when comparing with other carboxamide based derivatives. Urea and thiourea based 
compounds showed noticeable inhibition on protein denaturation, which is less than sulphonamide derivatives.      
The synthesized of compounds 4a and 4b could offer an excellent framework that may lead to the discovery of new potent 
anti-inflammatory agents. 
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4. CONCLUSION 
It could be concluded that compounds 4a (Synthesis of N-(4-(tosylamino) phenyl) indoline-1-carbothio amide) and 4b 
(Synthesis of N-(4-{[(2,6-dichlorophenyl)sulfonyl ]amino}phenyl) indoline-1-carbothioamide) showed potent inhibition on 
protein denaturation. Based on the above findings the novel indoline derivatives 4a, 4b selected for future optimisation 
and development in animal models for detailed efficacy studies.  
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